#475: Rethinking FDA Guidance: Why Non-Binding Documents Define Your Regulatory Strategy

In this episode of the Global Medical Device Podcast, host Etienne Nichols and regulatory consultant Mike Drues dive deep into the world of FDA guidance documents. They unpack what these documents truly represent—the agency's current thinking rather than binding law—and explore how manufacturers can navigate them effectively. The discussion covers the distinction between regulations in the Code of Federal Regulations and agency guidance, highlighting why a rigid, literal interpretation can be dangerous for product development.

The conversation examines the practical realities of using guidance documents as tactical tools and highlights the importance of proactive engagement with the agency. Mike shares valuable insights on challenging assumptions, understanding the shades of gray in regulatory compliance, and the strategic advantages of addressing deviations early through the pre-submission process. They also touch upon the limitations of the FDA guidance database and why revision history matters.

As part one of a two-part series, this episode lays the critical foundation for understanding how guidance shapes medical device development. Listeners will gain a fresh perspective on interacting with the FDA, moving beyond compliance checkboxes to build robust, defensible regulatory strategies. Stay tuned for part two, where the discussion shifts specifically to the fiscal year 2027 guidance list.

Takeaways

• Understand the distinction: Recognize that regulations in the CFR carry legal weight originating from Congress, whereas guidance documents represent FDA's current administrative or technical thinking and are technically non-binding.
• Avoid absolutism: Do not treat guidance documents as immutable laws; manufacturers can propose alternative approaches if they satisfy statutory and regulatory requirements.
• Leverage the pre-sub process: If your device strategy diverges from a published guidance document, address the deviation proactively during a pre-submission meeting rather than waiting for a rejection on your final submission.
• Look beyond the database: Use multiple search avenues—including broader web searches and direct inquiries through OICE/Dice—to track updates, historical revisions, and guidance documents currently in development.

References

• 21 CFR Part 10.115 - FDA’s Good Guidance Practices regulation outlining how guidance documents are developed and utilized.
• CDRH Guidance Document Database - The primary repository for current FDA medical device guidance documents.
• Etienne Nichols' LinkedIn - Connect with Etienne Nichols for more MedTech discussions and insights.

Sponsors

Greenlight Guru provides an industry-leading MedTech quality management solution that integrates both powerful QMS and EDC software onto a single platform.

Feedback Call-to-Action

We want to hear from you! What topics would you like us to cover in future episodes, or how are you navigating FDA guidance updates in your current projects? Send your thoughts, feedback, and topic suggestions directly to podcast@greenlight.guru, and our team will provide a personalized response. Don't forget to leave us a review!